Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

Pfizer moves to allow cheaper COVID-19 pills sending shares of rivals lower

Established COVID-19 vaccine makers have come under pressure after $Pfizer (PFE.US)$ and a United Nations-backed public health organization announced a licensing pact to allow generic-drugmakers to produce cheaper versions of the company’s experimental COVID-19 pill.
$Moderna (MRNA.US)$ , $AstraZeneca (AZN.US)$ , and Pfizer’s partner in COVID-19 vaccine development $BioNTech (BNTX.US)$ have lost ~1.4%, ~3.1%, and ~1.0% in the pre-market, respectively. $Johnson & Johnson (JNJ.US)$ is trading flat.
The licensing deal by Pfizer to enable wider access to its COVID-19 therapeutic follows a similar deal from the rival drugmaker $Merck & Co (MRK.US)$ for its investigational pill, molnupiravir. Merck has shed ~1.0% in early trading.
The shares of early-stage developers of oral COVID-19 therapies such as $Atea Pharmaceuticals (AVIR.US)$ / $ROCHE HOLDING AG (RHHBY.US)$ , $Redhill Biopharma (RDHL.US)$ , and $Adagio Therapeutics (ADGI.US)$ are also expected to open lower.
Stocks to watch: Established manufacturers of COVID-19 antibody treatments such as $Vir Biotechnology (VIR.US)$ , $Regeneron Pharmaceuticals (REGN.US)$ , $Eli Lilly and Co (LLY.US)$ as well as $Gilead Sciences (GILD.US)$ , which produces the intravenously administered COVID-19 therapy Remdesivir.
In terms of effectiveness, $Pfizer (PFE.US)$ and its rival $Merck & Co (MRK.US)$ have demonstrated about 89% and ~50% effectiveness for their oral COVID-19 drugs, PAXLOVID, and molnupiravir in late-stage trials, respectively.
Pfizer moves to allow cheaper COVID-19 pills sending shares of rivals lower
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
1
1
61
+0
8
Translate
Report
161K Views
Comment
Sign in to post a comment
493Followers
80Following
620Visitors
Follow